FDA invites patient groups to lead meetings

FDA formally invited patient groups to organize externally led meetings modeled on the agency's own patient-focused drug development (PFDD) initiative. In a Federal Register notice, the agency noted "growing external interest in expanding efforts to gather patient input."

Following a PFDD-style meeting initiated by the Amyloidosis Research Consortium in November, FDA Associate Director for Rare Diseases Jonathan Goldsmith told BioCentury it was open to supporting similar efforts by other stakeholders (see BioCentury, Dec. 7, 2015). ...